Amendments to the Claims:

Please cancel claims 25 and 32 and add new claims 49-56. Please amend claims 1-9, 11-15, 17-19, 21, 23-24, 26-31, and 48 as follows. This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of Formula (I):



(I)

or pharmaceutically acceptable salt thereof, wherein:

X is O, S, SO, SO_2, CO, COO, NR^7, $CONR^7$, $SONR^7$, SO_2NR^7, NR^7CONR^7 or is absent;

Y is C_1-C_{10} alkylenyl or is absent, wherein Y is optionally substituted by halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, hydroxy, carboxy, amino, alkylamino, or dialkylamino;

Z is O, S, SO, SO_2 or absent;

R^1 is H, C_1-C_8 alkyl, C_3-C_7 cycloalkyl, or C_1-C_8 haloalkyl;

R^2 is C_1-C_8 alkyl or C_1-C_8 haloalkyl;

R^3 is H, C_1-C_8 alkyl, or C_1-C_8 haloalkyl;

or R^2 and R^3 together with the C atom to which they are attached form a C_3-C_7 cycloalkyl ring;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, mercapto, C_1-C_8 alkoxy, C_1-C_8 thioalkoxy, C_1-C_8 haloalkoxy, aryloxy, cycloalkyloxy, heteroaryloxy, heterocycloalkyloxy, cyano, nitro, NR^8R^9, NR^8COR^{10}, COR^{10}, $COOR^{11}$, or $CONR^8R^9$;

R^7 is H, C_1-C_4 alkyl, or C_1-C_4 haloalkyl;

R^8 and R^9 are each, independently, H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_3-C_7 cycloalkyl, cycloalkylalkyl, aryl, or arylalkyl;

or R^8 and R^9 together with the N atom to which they are attached form a 5- or 6-membered heterocycloalkyl group;

R^{10} is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl;

R^{11} is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl;

Ar is aryl or heteroaryl, each optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_3-C_7 cycloalkyloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, mercapto, C_1-C_6 thioalkoxy, C_3-C_7 thiocycloalkyloxy, thioaryloxy, thioheteroaryloxy, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, C_1-C_4 haloalkylsulfinyl, C_1-C_4 haloalkylsulfonyl, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$, $NR^{14}COR^{12}$, $NR^{14}CONR^{14}R^{15}$, or $CONR^{14}R^{15}$;

or Ar together with Y and Z form a benzo-fused cycloalkyl or benzo-fused heterocycloalkyl group, each optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_3-C_7 cycloalkyloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, mercapto, C_1-C_6 thioalkoxy, C_3-C_7 thiocycloalkyloxy, thioaryloxy, thioheteroaryloxy, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, C_1-C_4 haloalkylsulfinyl, C_1-C_4 haloalkylsulfonyl, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$, $NR^{14}COR^{12}$, $NR^{14}CONR^{14}R^{15}$, or $CONR^{14}R^{15}$;

R^{12} is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl;

R^{13} is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl; and

R^{14} and R^{15} are each, independently, H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_3-C_7 cycloalkyl, cycloalkylalkyl, aryl, or arylalkyl;

or R^{14} and R^{15} together with the N atom to which they are attached form a 5- or 6-membered heterocycloalkyl group,

with the provisos:

~~a) when Ar-Z-Y-X- is bonded at position 7 or 8, and X is O, S or NR^7; Y is unsubstituted C_1-C_{10} alkylenyl or absent; and Z is absent, then Ar is substituted;~~

b) when Ar-Z-Y-X- is bonded at position 7 or 8, and X, Y and Z are absent, and Ar is aryl or aryl substituted with 1 substituent selected from the group consisting of C_{1-8} alkyl, halogen, perhaloalkyl, and alkoxy, then said aryl is further substituted with one substituent other than a substituent from the group consisting of C_{1-8} alkyl, halogen, perhaloalkyl, and alkoxy;

c) when Ar-Z-Y-X- is bonded at position 7 or 8, and X, Y and Z are absent, and Ar is aryl substituted with 2 substituents selected from C_{1-8} alkyl, halogen, perhaloalkyl, and alkoxy, then said aryl is further substituted with at least one substituent;

d) when Ar-Z-Y-X- is bonded at position 7 or 8, and X, Y and Z are absent, and Ar is heteroaryl or heteroaryl substituted with 1 substituent selected from the group consisting of halogen and C_{1-8} alkyl, then said heteroaryl is further substituted with one substituent other than a substituent from the group consisting of halogen and C_{1-8} alkyl; and

e) when Ar-Z-Y-X- is bonded at position 7 or 8, and X, Y and Z are absent, and Ar is heteroaryl substituted with 2 substituents selected from halogen and C_{1-8} alkyl, then said heteroaryl is further substituted with at least one substituent.

2. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein X is O, NR^7, $CONR^7$, or absent.

3. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein X is CO.

4. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein Ar is phenyl.

5. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein R^1 is H.

6. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein R^2 is C_1-C_4 alkyl.

7. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein R^2 is methyl.

8. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein R^3 is H.

9. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, or hydroxy.

10. (Original) The compound of claim 1 having Formula (IIa):



(IIa)

or pharmaceutically acceptable salt thereof.

11. (Currently amended) The compound of claim 10, or pharmaceutically acceptable salt thereof, wherein:

wherein:

X is O, CO, S, SO, SO_2, NR^7, $CONR^7$ or is absent;

Y is C_1-C_6 alkylenyl or is absent, wherein Y is optionally substituted by halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, hydroxy, carboxy, amino, alkylamino, or dialkylamino;

Z is O, S, or absent;

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_8 alkyl;

R^3 is H, C_1-C_8 alkyl, or C_1-C_8 haloalkyl;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, hydroxy, mercapto, C_1-C_4 alkoxy, or C_1-C_8 haloalkoxy; and

Ar is phenyl or pyridyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$;

or Ar together with Y and Z form a benzo-fused cycloalkyl or benzo-fused heterocycloalkyl group, each optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_3-C_7 cycloalkyloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, mercapto, C_1-C_6 thioalkoxy, C_3-C_7 thiocycloalkyloxy, thioaryloxy, thioheteroaryloxy, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, C_1-C_4 haloalkylsulfinyl, C_1-C_4 haloalkylsulfonyl, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$, $NR^{14}COR^{12}$, $NR^{14}CONR^{14}R^{15}$, or $CONR^{14}R^{15}$.

12. (Currently amended) The compound of claim 10, or pharmaceutically acceptable salt thereof, wherein:

X is CO;

Y is C_1-C_8 alkylenyl or absent;

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_4 alkyl;

R^3 is H, C_1-C_8 alkyl, or C_1-C_8 haloalkyl;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, hydroxy, mercapto, C_1-C_4 alkoxy, or C_1-C_4 haloalkoxy; and

Ar is phenyl substituted by one or more halo, cyano, nitro, C_1-C_4 alkyl, C_1-C_4 haloalkyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_4 alkoxy, or C_1-C_6 haloalkoxy.

13. (Currently amended) The compound of claim 10, or pharmaceutically acceptable salt thereof, wherein:

X is NR^7;

Y is C_1-C_6 alkylenyl;

Z is absent;

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_4 alkyl;

R^3 is H, C_1-C_8 alkyl, or C_1-C_8 haloalkyl;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, hydroxy, mercapto, C_1-C_4 alkoxy, or C_1-C_8 haloalkoxy; and

Ar is phenyl substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$;

or Ar together with Y and Z form a benzo-fused cycloalkyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$.

14. (Currently amended) The compound of claim 10, or pharmaceutically acceptable salt thereof, wherein:

X is $CONR^7$;

Y is C_1-C_6 alkylenyl or is absent;

Z is absent;

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_4 alkyl;

R^3 is H, C_1-C_8 alkyl, or C_1-C_8 haloalkyl;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, hydroxy, mercapto, C_1-C_4 alkoxy, or C_1-C_8 haloalkoxy; and

Ar is phenyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$.

15. (Currently amended) The compound of claim 10, or pharmaceutically acceptable salt thereof, wherein:

X is absent;

Y is C_1-C_6 alkylenyl;

Z is absent;

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_4 alkyl;

R^3 is H, C_1-C_8 alkyl, or C_1-C_8 haloalkyl;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, hydroxy, mercapto, C_1-C_4 alkoxy, or C_1-C_8 haloalkoxy; and

Ar is phenyl or pyridyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$.

16. (Original) The compound of claim 1 having Formula **(IIb)**:



(IIb)

or pharmaceutically acceptable salt thereof.

17. (Currently amended) The compound of claim 16, or pharmaceutically acceptable salt thereof, wherein:

X is O, NR^7, or is absent;

Y is C_1-C_6 alkylenyl or is absent, wherein Y is optionally substituted by halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, hydroxy, carboxy, amino, alkylamino, or dialkylamino;

Z is O, S, or absent;

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_8 alkyl;

R^3 is H;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, mercapto, C_1-C_8 alkoxy, C_1-C_8 thioalkoxy, C_1-C_8 haloalkoxy, aryloxy, cycloalkyloxy, heteroaryloxy, heterocycloalkyloxy, cyano, nitro, NR^8R^9, NR^8COR^{10}, COR^{10}, $COOR^{11}$, or $CONR^8R^9$; and

Ar is phenyl or pyridyl, each optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_3-C_7 cycloalkyloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, mercapto, C_1-C_6 thioalkoxy, C_3-C_7 thiocycloalkyloxy, thioaryloxy, thioheteroaryloxy, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, C_1-C_4 haloalkylsulfinyl, C_1-C_4 haloalkylsulfonyl, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$, $NR^{14}COR^{12}$, $NR^{14}CONR^{14}R^{15}$, or $CONR^{14}R^{15}$.

18. (Currently amended) The compound of claim 16, or pharmaceutically acceptable salt thereof, wherein:

X is absent;

Y is methylene or ethylene;

Z is absent;

R^1 is H or C_1-C_4 alkyl;

R^2 is methyl or ethyl;

R^3 is H;

R^4 and R^6 are both H;

R^5 is halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, hydroxy, C_1-C_8 alkoxy, C_1-C_8 haloalkoxy, cyano, nitro, or NR^8R^9; and

Ar is phenyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, or $NR^{14}R^{15}$.

19. (Currently amended) The compound of claim 16, or pharmaceutically acceptable salt thereof, wherein:

X is O;

Y is methylene or ethylene;

Z is O or absent;

R^1 is H or C_1-C_4 alkyl;

R^2 is methyl or ethyl;

R^3 is H;

R^4 and R^6 are both H;

R^5 is halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, hydroxy, C_1-C_8 alkoxy, C_1-C_8 haloalkoxy, cyano, nitro, or NR^8R^9; and

Ar is phenyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, or $NR^{14}R^{15}$.

20. (Original) The compound of claim 1 having Formula (**IId**):



(IId)

or pharmaceutically acceptable salt thereof.

21. (Currently amended) The compound of claim 20, or pharmaceutically acceptable salt thereof, wherein:

X is absent;

Y is methylene or ethylene;

Z is absent;

R^1 is H or C_1-C_4 alkyl;

R^2 is methyl or ethyl;

R^3 is H;

R^4 and R^5 are both H;

R^6 is halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, hydroxy, C_1-C_8 alkoxy, C_1-C_8 haloalkoxy, cyano, nitro, or NR^8R^9; and

Ar is phenyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, or $NR^{14}R^{15}$.

22. (Original) The compound of claim 1 selected from:

a) 1-methyl-8-(2-phenoxy-ethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

b) (4-fluoro-benzyl)-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

c) biphenyl-4-ylmethyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

d) 5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7-carboxylic acid phenylamide;

e) 5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7-carboxylic acid benzylamide;

f) 5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7-carboxylic acid phenethylamide;

g) 5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7-carboxylic acid phenpropylamide;

h) 5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7-carboxylic acid 4-phenylbenzylamide;

i) [2-(3,4-dimethoxy-phenyl)-ethyl]-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

j) 8-benzyl-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

k) indan-1'-yl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

l) 7-benzyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

m) 8-benzyl-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; and

n) 6-Benzyl-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol;

or pharmaceutically acceptable salt thereof.

23. (Currently amended) The compound of claim 1 selected from:

a) 8-(3-Methoxy-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

b) 8-Benzyl-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

c) 8-Benzyl-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

d) 8-Benzyl-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol;

e) 1-Methyl-8-phenethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

f) 8-(2-Fluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

g) 8-(3-Fluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

h) 8-(4-Fluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

i) 1-Methyl-8-(3-trifluoromethyl-benzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

j) 8-(2,6-Difluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

k) 8-(2,4-difluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

l) 8-(2,5-Difluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

m) 8-(3,5-difluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

n) 8-(3,4-Difluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

o) 8-(2-Methoxy-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

p) 8-(4-Methoxy-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

q) 1-Methyl-8-(1-phenyl-ethyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

r) (8-Methoxy-5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenyl-methanone;

s) (5-Methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenyl-methanone;

t) 6-Benzyl-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol;

u) 8-Benzyl-7-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

v) 8-(3-Fluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol; and

w) 7-(3-Fluoro-benzyloxy)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

or pharmaceutically acceptable salt thereof ~~acceptable salts~~.

24. (Currently amended) A composition comprising a compound of claim 1, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

25. (Canceled)

26. (Currently amended) ~~The method~~ A method of treating a disorder ~~of claim 25 wherein the disorders of the central nervous system are~~ selected from depression, atypical depression, ~~bipolar disorders,~~ anxiety ~~disorders~~, obsessive-compulsive disorder[[s]], social phobia[[s or]], panic states, ~~sleep disorders,~~ sexual dysfunction, psychoses, schizophrenia, ~~migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure,~~ epilepsy, ~~personality disorders, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome,~~ drug and alcohol addiction, and obesity, ~~bulimia,~~

~~anorexia nervosa and premenstrual tension~~ comprising administering to a patient in need of said treating a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salt thereof.

27. (Currently amended) The method according to ~~claim 25~~ claim 26 wherein the disorder ~~of the central nervous system~~ is obesity.

28. (Currently amended) The method according to ~~claim 25~~ claim 26 wherein the sexual dysfunction is male erectile dysfunction.

29. (Currently amended) A method of decreasing food intake of a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salt thereof.

30. (Currently amended) A method of inducing satiety in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salt thereof.

31. (Currently amended) A method of controlling weight gain of a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salt thereof.

32-47. (Canceled)

48. (Currently amended) A method for preparing a pharmaceutical composition comprising the step of mixing a compound**[[s]]** of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

49. (New) The method according to claim 26 wherein the disorder is depression.

50. (New) The method according to claim 26 wherein the disorder is anxiety.

51. (New) The method according to claim 26 wherein the disorder is obsessive-compulsive disorder.

52. (New) The method according to claim 26 wherein the disorder is social phobia.

53. (New) The method according to claim 26 wherein the disorder is panic states.

54. (New) The method according to claim 26 wherein the disorder is psychoses.

55. (New) The method according to claim 26 wherein the disorder is schizophrenia.

56. (New) The method according to claim 26 wherein the disorder is selected from drug and alcohol addiction.